Active Therapy with Passive Immunotherapy May Be Effective in the Fight against Covid-19.
Identifieur interne : 002122 ( Ncbi/Merge ); précédent : 002121; suivant : 002123Active Therapy with Passive Immunotherapy May Be Effective in the Fight against Covid-19.
Auteurs : Christopher J. Morabito [Autriche] ; Bagirath Gangadharan [Autriche]Source :
- Clinical and translational science [ 1752-8062 ] ; 2020.
Abstract
Passive immunity against pathogens in epidemics has historical roots. Convalescent plasma (CP), plasma collected from individuals who have recovered from an infectious disease, has been used to confer therapeutic benefits in previous epidemics, including measles, mumps, and influenza, and remains the first line passive immunotherapy in emerging diseases, including the H1N1 influenza pandemic (2009) and now Covid-19 (1). Over the last several decades, as technology has developed to purify and manufacture plasma-derived immunoglobulin (IG) as a drug therapy, hyperimmune globulin (H-IG) formulations have been used as the second line of passive immunotherapies against these diseases.
DOI: 10.1111/cts.12816
PubMed: 32420691
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000006
- to stream PubMed, to step Curation: 000006
- to stream PubMed, to step Checkpoint: 000059
Links to Exploration step
pubmed:32420691Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Active Therapy with Passive Immunotherapy May Be Effective in the Fight against Covid-19.</title><author><name sortKey="Morabito, Christopher J" sort="Morabito, Christopher J" uniqKey="Morabito C" first="Christopher J" last="Morabito">Christopher J. Morabito</name><affiliation wicri:level="1"><nlm:affiliation>Takeda Pharmaceuticals, Massachusetts and Vienna, Cambridge, Austria.</nlm:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>Takeda Pharmaceuticals, Massachusetts and Vienna, Cambridge</wicri:regionArea><wicri:noRegion>Cambridge</wicri:noRegion></affiliation></author><author><name sortKey="Gangadharan, Bagirath" sort="Gangadharan, Bagirath" uniqKey="Gangadharan B" first="Bagirath" last="Gangadharan">Bagirath Gangadharan</name><affiliation wicri:level="1"><nlm:affiliation>Takeda Pharmaceuticals, Massachusetts and Vienna, Cambridge, Austria.</nlm:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>Takeda Pharmaceuticals, Massachusetts and Vienna, Cambridge</wicri:regionArea><wicri:noRegion>Cambridge</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32420691</idno><idno type="pmid">32420691</idno><idno type="doi">10.1111/cts.12816</idno><idno type="wicri:Area/PubMed/Corpus">000006</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000006</idno><idno type="wicri:Area/PubMed/Curation">000006</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000006</idno><idno type="wicri:Area/PubMed/Checkpoint">000059</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000059</idno><idno type="wicri:Area/Ncbi/Merge">002122</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Active Therapy with Passive Immunotherapy May Be Effective in the Fight against Covid-19.</title><author><name sortKey="Morabito, Christopher J" sort="Morabito, Christopher J" uniqKey="Morabito C" first="Christopher J" last="Morabito">Christopher J. Morabito</name><affiliation wicri:level="1"><nlm:affiliation>Takeda Pharmaceuticals, Massachusetts and Vienna, Cambridge, Austria.</nlm:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>Takeda Pharmaceuticals, Massachusetts and Vienna, Cambridge</wicri:regionArea><wicri:noRegion>Cambridge</wicri:noRegion></affiliation></author><author><name sortKey="Gangadharan, Bagirath" sort="Gangadharan, Bagirath" uniqKey="Gangadharan B" first="Bagirath" last="Gangadharan">Bagirath Gangadharan</name><affiliation wicri:level="1"><nlm:affiliation>Takeda Pharmaceuticals, Massachusetts and Vienna, Cambridge, Austria.</nlm:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>Takeda Pharmaceuticals, Massachusetts and Vienna, Cambridge</wicri:regionArea><wicri:noRegion>Cambridge</wicri:noRegion></affiliation></author></analytic><series><title level="j">Clinical and translational science</title><idno type="eISSN">1752-8062</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Passive immunity against pathogens in epidemics has historical roots. Convalescent plasma (CP), plasma collected from individuals who have recovered from an infectious disease, has been used to confer therapeutic benefits in previous epidemics, including measles, mumps, and influenza, and remains the first line passive immunotherapy in emerging diseases, including the H1N1 influenza pandemic (2009) and now Covid-19 (1). Over the last several decades, as technology has developed to purify and manufacture plasma-derived immunoglobulin (IG) as a drug therapy, hyperimmune globulin (H-IG) formulations have been used as the second line of passive immunotherapies against these diseases.</div></front></TEI><pubmed><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">32420691</PMID><DateRevised><Year>2020</Year><Month>05</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1752-8062</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2020</Year><Month>May</Month><Day>18</Day></PubDate></JournalIssue><Title>Clinical and translational science</Title><ISOAbbreviation>Clin Transl Sci</ISOAbbreviation></Journal><ArticleTitle>Active Therapy with Passive Immunotherapy May Be Effective in the Fight against Covid-19.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1111/cts.12816</ELocationID><Abstract><AbstractText>Passive immunity against pathogens in epidemics has historical roots. Convalescent plasma (CP), plasma collected from individuals who have recovered from an infectious disease, has been used to confer therapeutic benefits in previous epidemics, including measles, mumps, and influenza, and remains the first line passive immunotherapy in emerging diseases, including the H1N1 influenza pandemic (2009) and now Covid-19 (1). Over the last several decades, as technology has developed to purify and manufacture plasma-derived immunoglobulin (IG) as a drug therapy, hyperimmune globulin (H-IG) formulations have been used as the second line of passive immunotherapies against these diseases.</AbstractText><CopyrightInformation>This article is protected by copyright. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Morabito</LastName><ForeName>Christopher J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Takeda Pharmaceuticals, Massachusetts and Vienna, Cambridge, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gangadharan</LastName><ForeName>Bagirath</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Takeda Pharmaceuticals, Massachusetts and Vienna, Cambridge, Austria.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>05</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Transl Sci</MedlineTA><NlmUniqueID>101474067</NlmUniqueID><ISSNLinking>1752-8054</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>5</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>5</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>5</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32420691</ArticleId><ArticleId IdType="doi">10.1111/cts.12816</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Autriche</li></country></list><tree><country name="Autriche"><noRegion><name sortKey="Morabito, Christopher J" sort="Morabito, Christopher J" uniqKey="Morabito C" first="Christopher J" last="Morabito">Christopher J. Morabito</name></noRegion><name sortKey="Gangadharan, Bagirath" sort="Gangadharan, Bagirath" uniqKey="Gangadharan B" first="Bagirath" last="Gangadharan">Bagirath Gangadharan</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002122 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 002122 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= PandemieGrippaleV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:32420691
|texte= Active Therapy with Passive Immunotherapy May Be Effective in the Fight against Covid-19.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:32420691" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a PandemieGrippaleV1
| This area was generated with Dilib version V0.6.34. |  |